Skip to main content
Fig. 1 | Cardio-Oncology

Fig. 1

From: Concomitant use of renin-angiotensin-aldosterone system inhibitors prevent trastuzumab-induced cardiotoxicity in HER2+ breast cancer patients: an institutional retrospective study

Fig. 1

Flow chart of patients included and excluded from the study. A total of 417 patients with HER2+ breast cancer were identified from our institution’s tumor registry. The total number of patients with confirmed HER2+ by pathological and FISH analysis who received TRA was 127. Patients that were excluded totalled 108 as above

Back to article page

Cardio-Oncology

ISSN: 2057-3804

Contact us